• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社会心理生活质量是新诊断的多发性骨髓瘤患者总生存期的独立预测因素。

Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma.

作者信息

Strasser-Weippl Kathrin, Ludwig Heinz

机构信息

1st Medical Department, Center for Haematology and Medical Oncology, Wilhelminenspital, Vienna, Austria.

出版信息

Eur J Haematol. 2008 Nov;81(5):374-9. doi: 10.1111/j.1600-0609.2008.01126.x. Epub 2008 Jul 11.

DOI:10.1111/j.1600-0609.2008.01126.x
PMID:18637124
Abstract

Only few studies have analyzed quality of life (QOL) and its association with prognosis in patients with multiple myeloma. We studied QOL at start of conventional treatment to evaluate the impact of symptomatic myeloma on QOL and to determine the prognostic significance of various dimensions of QOL. Our study provided further evidence of the significant impairment of QOL in patients with multiple myeloma at onset of therapy. Furthermore, our data showed a closer correlation between the more physical QOL scales such as pain, fatigue, physical functioning and global QOL with the activity of the disease than between psychosocial dimensions such as role, emotional, social, and cognitive functioning and the status of the disease. Multivariate analyses including each a QOL scale and known prognostic parameters (response to therapy, creatinine level, calcium, LDH, Hb, beta2-microglobulin, and albumin) revealed a marked difference in the prognostic significance between psychosocial and other QOL scales. All psychosocial dimensions of QOL were found to be independent prognostic factors, while physical QOL and global QOL were eliminated by disease-associated prognosticators. Taken together, QOL was found to be significantly impaired in myeloma patients at start of therapy. Psychosocial, but not physical dimensions of QOL were found to be independent prognostic factors.

摘要

仅有少数研究分析了多发性骨髓瘤患者的生活质量(QOL)及其与预后的关联。我们在传统治疗开始时研究了生活质量,以评估有症状的骨髓瘤对生活质量的影响,并确定生活质量各维度的预后意义。我们的研究进一步证明了多发性骨髓瘤患者在治疗开始时生活质量受到显著损害。此外,我们的数据显示,与角色、情感、社会和认知功能等心理社会维度相比,疼痛、疲劳、身体功能和总体生活质量等更多身体方面的生活质量量表与疾病活动之间的相关性更强。包括各生活质量量表和已知预后参数(对治疗的反应、肌酐水平、钙、乳酸脱氢酶、血红蛋白、β2-微球蛋白和白蛋白)的多变量分析显示,心理社会生活质量量表与其他生活质量量表在预后意义上存在显著差异。发现生活质量的所有心理社会维度都是独立的预后因素,而身体生活质量和总体生活质量则被疾病相关的预后因素所排除。综上所述,骨髓瘤患者在治疗开始时生活质量明显受损。发现生活质量的心理社会维度而非身体维度是独立的预后因素。

相似文献

1
Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma.社会心理生活质量是新诊断的多发性骨髓瘤患者总生存期的独立预测因素。
Eur J Haematol. 2008 Nov;81(5):374-9. doi: 10.1111/j.1600-0609.2008.01126.x. Epub 2008 Jul 11.
2
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.生活质量受疾病参数和治疗反应的影响可能比血红蛋白变化的影响更大。
Eur J Haematol. 2005 Oct;75(4):293-8. doi: 10.1111/j.1600-0609.2005.00509.x.
3
The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma.多发性骨髓瘤患者生理变量、生活质量和疲劳之间的关系。
Oncol Nurs Forum. 2009 Mar;36(2):209-16. doi: 10.1188/09.ONF.209-216.
4
Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.接受大剂量化疗后自体外周血祖细胞移植的多发性骨髓瘤幸存者的健康相关生活质量:一项回顾性分析。
Neoplasma. 2008;55(4):350-5.
5
Serum calcium is an independent predictor of quality of life in multiple myeloma.
Eur J Haematol. 2007 Jan;78(1):29-34. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2887.x. Epub 2006 Oct 13.
6
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.利用游离β2微球蛋白的HLA I类重链血清水平以及IgM或血小板计数对活动性疾病的多发性骨髓瘤患者进行分期。
Blood Cells Mol Dis. 2009 Jan-Feb;42(1):71-6. doi: 10.1016/j.bcmd.2008.09.003. Epub 2008 Nov 7.
7
Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.多发性骨髓瘤患者的简易预后模型:日本的一项单中心研究
Ann Hematol. 2002 Jan;81(1):33-6. doi: 10.1007/s00277-001-0388-5. Epub 2001 Nov 10.
8
[Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].多发性骨髓瘤临床分期系统的预后分析与评估——附206例报告
Ai Zheng. 2006 Apr;25(4):461-4.
9
[Prognostic value of serum beta2-microglobulin in multiple myeloma].[血清β2微球蛋白在多发性骨髓瘤中的预后价值]
Recenti Prog Med. 2005 Feb;96(2):81-6.
10
Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.动态对比增强磁共振成像测量的腰椎骨髓微循环是进展性多发性骨髓瘤无事件生存期的一个预测指标。
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):475-81. doi: 10.1158/1078-0432.CCR-06-0061.

引用本文的文献

1
Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study.接受嵌合抗原受体T细胞(CAR-T)疗法的血液系统恶性肿瘤患者的生活质量和症状负担:一项横断面研究。
Sci Rep. 2025 May 22;15(1):17763. doi: 10.1038/s41598-025-02720-6.
2
The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states.不同形式的社会支持对多发性骨髓瘤及其前体状态患者的健康相关生活质量的影响。
J Cancer Res Clin Oncol. 2024 Jan 31;150(2):55. doi: 10.1007/s00432-023-05570-9.
3
Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials.
多发性骨髓瘤临床试验中患者报告结局的使用与报告指南。
Cancers (Basel). 2023 Dec 8;15(24):5764. doi: 10.3390/cancers15245764.
4
High patient satisfaction and increased physical activity following a remote multidisciplinary team multiple myeloma clinic.远程多学科团队多发性骨髓瘤门诊治疗后,患者满意度高,身体活动增加。
Support Care Cancer. 2023 Jan 21;31(2):127. doi: 10.1007/s00520-023-07587-9.
5
Quality of life of patients with hematological malignancies and factors affecting health state utility values.血液恶性肿瘤患者的生活质量及影响健康状态效用值的因素。
Support Care Cancer. 2022 Jun;30(6):5319-5327. doi: 10.1007/s00520-022-06958-y. Epub 2022 Mar 12.
6
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.台湾南部移植不适用的骨髓瘤患者接受硼替佐米联合沙利度胺加地塞米松(VTD)或硼替佐米联合美法仑加泼尼松(VMP)治疗的成本效益分析
J Pers Med. 2022 Jan 19;12(2):130. doi: 10.3390/jpm12020130.
7
An Individualized Exercise Intervention for People with Multiple Myeloma-Study Protocol of a Randomized Waitlist-Controlled Trial.一项针对多发性骨髓瘤患者的个体化运动干预研究方案:一项随机等待期对照试验。
Curr Oncol. 2022 Feb 7;29(2):901-923. doi: 10.3390/curroncol29020077.
8
Lifestyle considerations in multiple myeloma.多发性骨髓瘤的生活方式考虑因素。
Blood Cancer J. 2021 Oct 26;11(10):172. doi: 10.1038/s41408-021-00560-x.
9
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.多发性骨髓瘤患者临床试验以外的治疗管理:了解疗效、安全性和耐受性以及生活质量之间的平衡。
Blood Cancer J. 2021 Feb 18;11(2):40. doi: 10.1038/s41408-021-00432-4.
10
Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program.多发性骨髓瘤患者参与多学科康复计划的健康相关生活质量。
Ann Hematol. 2021 Sep;100(9):2311-2323. doi: 10.1007/s00277-020-04356-0. Epub 2021 Jan 6.